Tags

Type your tag names separated by a space and hit enter

Apomorphine hydrochloride for the treatment of Parkinson's disease.
Expert Rev Neurother. 2015; 15(7):723-32.ER

Abstract

Apomorphine (APO) is a potent D1 and D2 dopamine agonist. Plasma maximal concentration is reached in 8-16 min with a plasma half-life of 34-70 min. Bioavailability is close to 100%. It has a rapid antiparkinsonian action after subcutaneous (s.c.) administration with a size effect comparable with that of levodopa. Trials of s.c., oral, sublingual, intravenous, rectal, intranasal and iontophoretic transdermal administration of APO have been attempted in Parkinson's disease (PD), each of these routes have shown some potential for clinical effectiveness but the majority of studies indicate that APO intermittent s.c. administration, on which this review is mainly focused, is an effective therapy for the management of motor symptoms in PD, particularly in advanced phases mainly characterized by motor fluctuations, such as wearing OFF and unpredictable "off". Data on the effect of APO on non-motor symptoms in PD patients are limited but there is strong suggestion of a beneficial effect that warrants further investigation.

Authors+Show Affiliations

University of Pisa - Clinical and Experimental Medicine-Neurology Unit, via Roma 56, Pisa 56126, Italy.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

26037961

Citation

Unti, Elisa, et al. "Apomorphine Hydrochloride for the Treatment of Parkinson's Disease." Expert Review of Neurotherapeutics, vol. 15, no. 7, 2015, pp. 723-32.
Unti E, Ceravolo R, Bonuccelli U. Apomorphine hydrochloride for the treatment of Parkinson's disease. Expert Rev Neurother. 2015;15(7):723-32.
Unti, E., Ceravolo, R., & Bonuccelli, U. (2015). Apomorphine hydrochloride for the treatment of Parkinson's disease. Expert Review of Neurotherapeutics, 15(7), 723-32. https://doi.org/10.1586/14737175.2015.1051468
Unti E, Ceravolo R, Bonuccelli U. Apomorphine Hydrochloride for the Treatment of Parkinson's Disease. Expert Rev Neurother. 2015;15(7):723-32. PubMed PMID: 26037961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Apomorphine hydrochloride for the treatment of Parkinson's disease. AU - Unti,Elisa, AU - Ceravolo,Roberto, AU - Bonuccelli,Ubaldo, Y1 - 2015/06/02/ PY - 2015/6/4/entrez PY - 2015/6/4/pubmed PY - 2016/3/22/medline KW - Parkinson’s KW - apomorphine KW - disease KW - intermittent KW - motor fluctuations KW - subcutaneous KW - therapy SP - 723 EP - 32 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 15 IS - 7 N2 - Apomorphine (APO) is a potent D1 and D2 dopamine agonist. Plasma maximal concentration is reached in 8-16 min with a plasma half-life of 34-70 min. Bioavailability is close to 100%. It has a rapid antiparkinsonian action after subcutaneous (s.c.) administration with a size effect comparable with that of levodopa. Trials of s.c., oral, sublingual, intravenous, rectal, intranasal and iontophoretic transdermal administration of APO have been attempted in Parkinson's disease (PD), each of these routes have shown some potential for clinical effectiveness but the majority of studies indicate that APO intermittent s.c. administration, on which this review is mainly focused, is an effective therapy for the management of motor symptoms in PD, particularly in advanced phases mainly characterized by motor fluctuations, such as wearing OFF and unpredictable "off". Data on the effect of APO on non-motor symptoms in PD patients are limited but there is strong suggestion of a beneficial effect that warrants further investigation. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/26037961/Apomorphine_hydrochloride_for_the_treatment_of_Parkinson's_disease_ L2 - http://www.tandfonline.com/doi/full/10.1586/14737175.2015.1051468 DB - PRIME DP - Unbound Medicine ER -